JPWO2019217591A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019217591A5 JPWO2019217591A5 JP2020562649A JP2020562649A JPWO2019217591A5 JP WO2019217591 A5 JPWO2019217591 A5 JP WO2019217591A5 JP 2020562649 A JP2020562649 A JP 2020562649A JP 2020562649 A JP2020562649 A JP 2020562649A JP WO2019217591 A5 JPWO2019217591 A5 JP WO2019217591A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- alkyl
- amino acid
- seq
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000126 substance Substances 0.000 description 66
- 125000000217 alkyl group Chemical group 0.000 description 52
- 230000027455 binding Effects 0.000 description 46
- 108090001123 antibodies Proteins 0.000 description 41
- 102000004965 antibodies Human genes 0.000 description 41
- 239000000611 antibody drug conjugate Substances 0.000 description 41
- 108091008116 antibody drug conjugates Proteins 0.000 description 41
- 239000000427 antigen Substances 0.000 description 36
- 108091007172 antigens Proteins 0.000 description 36
- 102000038129 antigens Human genes 0.000 description 36
- 125000005647 linker group Chemical group 0.000 description 28
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 18
- 239000000562 conjugate Substances 0.000 description 14
- 102100004660 MSR1 Human genes 0.000 description 13
- 101700001066 MSR1 Proteins 0.000 description 13
- 229910052739 hydrogen Inorganic materials 0.000 description 13
- 239000001257 hydrogen Substances 0.000 description 13
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- 125000003275 alpha amino acid group Chemical group 0.000 description 12
- 150000001875 compounds Chemical group 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 239000012453 solvate Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- HJYYPODYNSCCOU-ODRIEIDWSA-N MDL-62769 Chemical group OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 230000000051 modifying Effects 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 125000003710 aryl alkyl group Chemical group 0.000 description 6
- 125000004429 atoms Chemical group 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 150000003431 steroids Chemical group 0.000 description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 201000009910 diseases by infectious agent Diseases 0.000 description 5
- 125000005842 heteroatoms Chemical group 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 229940076185 Staphylococcus aureus Drugs 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 108010016626 Dipeptides Proteins 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 150000002829 nitrogen Chemical group 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 2
- 206010060945 Bacterial infection Diseases 0.000 description 2
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 description 2
- 125000000732 arylene group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- -1 but not limited to Chemical group 0.000 description 2
- 210000004027 cells Anatomy 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 125000004474 heteroalkylene group Chemical group 0.000 description 2
- 125000005549 heteroarylene group Chemical group 0.000 description 2
- 200000000018 inflammatory disease Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 201000010874 syndrome Diseases 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 235000014393 valine Nutrition 0.000 description 2
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- 125000000981 3-amino-3-oxopropyl group Chemical group [H]C([*])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003246 Arthritis Diseases 0.000 description 1
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- 206010064687 Device related infection Diseases 0.000 description 1
- 206010058108 Dyslipidaemia Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010014665 Endocarditis Diseases 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 206010015988 Eyelid infection Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline zwitterion Chemical group NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- 206010061227 Lipid metabolism disease Diseases 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- 210000002264 Mammary Glands, Animal Anatomy 0.000 description 1
- 210000004293 Mammary Glands, Human Anatomy 0.000 description 1
- 208000008466 Metabolic Disease Diseases 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 229940010383 Mycobacterium tuberculosis Drugs 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 206010030861 Ophthalmia neonatorum Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 102000014452 Scavenger Receptors Human genes 0.000 description 1
- 108010078070 Scavenger Receptors Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 206010040893 Skin necrosis Diseases 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N VANCOMYCIN Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 Vancomycin Drugs 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 201000001320 atherosclerosis Diseases 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000002860 competitive Effects 0.000 description 1
- 201000010870 diseases of metabolism Diseases 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 201000009906 meningitis Diseases 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000000626 neurodegenerative Effects 0.000 description 1
- 230000002062 proliferating Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862669276P | 2018-05-09 | 2018-05-09 | |
| US62/669,276 | 2018-05-09 | ||
| US201862678200P | 2018-05-30 | 2018-05-30 | |
| US62/678,200 | 2018-05-30 | ||
| US201862769946P | 2018-11-20 | 2018-11-20 | |
| US62/769,946 | 2018-11-20 | ||
| US201962789987P | 2019-01-08 | 2019-01-08 | |
| US62/789,987 | 2019-01-08 | ||
| US201962821362P | 2019-03-20 | 2019-03-20 | |
| US62/821,362 | 2019-03-20 | ||
| PCT/US2019/031383 WO2019217591A1 (en) | 2018-05-09 | 2019-05-08 | Anti-msr1 antibodies and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021523147A JP2021523147A (ja) | 2021-09-02 |
| JPWO2019217591A5 true JPWO2019217591A5 (es) | 2022-06-02 |
Family
ID=66625372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020562649A Pending JP2021523147A (ja) | 2018-05-09 | 2019-05-08 | 抗ｍｓｒ１抗体及びその使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11377502B2 (es) |
| EP (1) | EP3790899A1 (es) |
| JP (1) | JP2021523147A (es) |
| KR (1) | KR20210008008A (es) |
| CN (1) | CN112533951A (es) |
| AU (1) | AU2019265703A1 (es) |
| BR (1) | BR112020022400A2 (es) |
| CA (1) | CA3098453A1 (es) |
| CL (1) | CL2020002873A1 (es) |
| CO (1) | CO2020015084A2 (es) |
| MX (1) | MX2020011546A (es) |
| PH (1) | PH12020551865A1 (es) |
| SG (1) | SG11202010909RA (es) |
| WO (1) | WO2019217591A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017359043B2 (en) | 2016-11-08 | 2022-06-16 | Regeneron Pharmaceuticals, Inc. | Steroids and protein-conjugates thereof |
| AU2018270784B2 (en) | 2017-05-18 | 2024-05-16 | Regeneron Pharmaceuticals, Inc. | Cyclodextrin protein drug conjugates |
| WO2018213082A1 (en) * | 2017-05-18 | 2018-11-22 | Regeneron Pharmaceuticals, Inc. | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof |
| AU2019205542A1 (en) * | 2018-01-08 | 2020-07-16 | Regeneron Pharmaceuticals, Inc. | Steroids and antibody-conjugates thereof |
| KR20210094568A (ko) | 2018-11-20 | 2021-07-29 | 리제너론 파마슈티칼스 인코포레이티드 | Lxr 작용물질로서 사용하기 위한 비스-옥타하이드로펜안트렌 카복스아미드 유도체 및 그의 단백질 접합체 |
| US11666658B2 (en) * | 2018-12-21 | 2023-06-06 | Regeneran Pharmaceuticals, Inc. | Rifamycin analogs and antibody-drug conjugates thereof |
| CN113905767A (zh) | 2019-01-08 | 2022-01-07 | 里珍纳龙药品有限公司 | 无痕连接体及其蛋白质偶联物 |
| US20230220065A1 (en) * | 2020-06-16 | 2023-07-13 | Academia Sinica | Antibodies to interleukin-1beta and uses thereof |
| IL299153A (en) * | 2020-07-13 | 2023-02-01 | Regeneron Pharma | Camptothecin analogs conjugated to a glutamine residue in protein, and their uses |
| CN114605367B (zh) * | 2020-12-03 | 2023-06-27 | 中国人民解放军军事科学院军事医学研究院 | 含香豆素的连接子及含该连接子的抗体偶联药物 |
| EP4308170A1 (en) | 2021-03-18 | 2024-01-24 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| CN117098540A (zh) * | 2021-03-26 | 2023-11-21 | 瑞泽恩制药公司 | 与万古霉素联合的利福霉素类似物及其用途 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| CN115671308A (zh) * | 2021-07-30 | 2023-02-03 | 北京键凯科技股份有限公司 | 一种靶向性的抗体-聚乙二醇-siRNA药物偶联物 |
| CN115594766A (zh) * | 2021-12-30 | 2023-01-13 | 辽宁键凯科技有限公司（Cn） | 一种缀合物及用其制备的抗体偶联药物 |
| CA3241734A1 (en) * | 2022-01-12 | 2023-07-20 | Amy Han | Camptothecin analogs conjugated to a glutamine residue in a protein, and their use |
| US20240067640A1 (en) | 2022-03-11 | 2024-02-29 | Firefly Bio, Inc. | Phenyl maleimide linker agents |
| WO2024059237A2 (en) * | 2022-09-15 | 2024-03-21 | Adcentrx Therapeutics Inc. | Novel glucocorticoid receptor agonists and immunoconjugates thereof |
Family Cites Families (139)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB889766A (en) | 1958-03-04 | 1962-02-21 | Olin Mathieson | Improvements in steroids and the synthesis thereof |
| DE1165595B (de) | 1958-03-04 | 1964-03-19 | Olin Mathieson | Verfahren zur Herstellung von Triamcinolonacetonid-21-hemisuccinat und dessen Salzen |
| US3197469A (en) | 1958-08-06 | 1965-07-27 | Pharmaceutical Res Products In | 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor |
| US3007923A (en) | 1959-01-22 | 1961-11-07 | Lab Francais Chimiotherapie | Process for the fluorination of 9beta, 11beta-epoxy and 5alpha, 6alpha-epoxy steroids |
| GB898291A (en) | 1959-03-18 | 1962-06-06 | Upjohn Co | Improvements in or relating to steroids and the manufacture thereof |
| US3033874A (en) | 1960-05-11 | 1962-05-08 | Pfizer & Co C | 17beta-propenoyl steroids and process for preparing same |
| US3033873A (en) | 1960-05-11 | 1962-05-08 | Pfizer & Co C | 21-aminomethyl-pregnenes |
| US3020275A (en) | 1960-06-07 | 1962-02-06 | American Cyanamid Co | 21-nitrogen substituted steroids of the pregnane series and methods of preparing the same |
| DE1169444B (de) | 1961-02-22 | 1964-05-06 | Schering Ag | Verfahren zur Herstellung von ?-16ª-Methylsteroiden |
| US3047468A (en) | 1961-06-06 | 1962-07-31 | American Cyanamid Co | Method of preparing delta1, 4-3-keto steroids of the pregnane series |
| US3383394A (en) | 1965-08-30 | 1968-05-14 | Schering Corp | Novel 17-acylating process and products thereof |
| US3798216A (en) | 1969-03-07 | 1974-03-19 | Fabrication Des Antibiotique S | 9-fluoro-11beta,21-dihydroxy-16alpha,17-(2-propenylidenedioxy)-pregna-1,4-diene-3,20-dione and derivatives thereof |
| DE2047105C3 (de) | 1970-09-18 | 1979-02-15 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | 17-Chlorsteroide und Verfahren zu ihrer Herstellung |
| IT1057859B (it) | 1972-04-28 | 1982-03-30 | Sigma Tao Ind Farmaceutiche Sp | Perivato del triamoinolone |
| SE378110B (es) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
| SE378109B (es) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
| SE8604059D0 (sv) | 1986-09-25 | 1986-09-25 | Astra Pharma Prod | A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5116829A (en) | 1990-04-23 | 1992-05-26 | Kao Corporation | Steroid compounds |
| US5183815A (en) | 1991-01-22 | 1993-02-02 | Merck & Co., Inc. | Bone acting agents |
| LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
| NZ259596A (en) | 1993-01-08 | 1997-04-24 | Astra Ab | Sugar-substituted glucocorticosteroid and use in medicaments specific to the colon or ileum |
| DE4311987A1 (de) | 1993-04-07 | 1994-10-13 | Schering Ag | Neue Glucocorticoide |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5824669A (en) | 1996-03-22 | 1998-10-20 | Nitromed, Inc. | Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders |
| US5837698A (en) | 1996-05-02 | 1998-11-17 | G. D. Searle & Co. | Steroid nitrite and nitrate ester derivatives useful as anti-inflammatory drugs |
| WO2000049993A2 (en) | 1999-02-24 | 2000-08-31 | Nitromed, Inc. | Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| SE0101220D0 (sv) | 2001-04-04 | 2001-04-04 | Astrazeneca Ab | New use |
| US6908934B2 (en) | 2001-06-11 | 2005-06-21 | Merck & Co., Inc. | Therapeutic compounds for treating dyslipidemic conditions |
| ITMI20020148A1 (it) | 2002-01-29 | 2003-07-29 | Nicox Sa | Nuovi corticosteroidi |
| US20050009798A1 (en) | 2002-02-20 | 2005-01-13 | Sepracor Inc. | Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists |
| US7190468B2 (en) | 2002-07-17 | 2007-03-13 | Hewlett-Packard Development Company, L.P. | Background document rendering system and method |
| SI1545613T1 (sl) | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| KR20140070676A (ko) | 2002-09-06 | 2014-06-10 | 인설트 테라페틱스, 인코퍼레이티드 | 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체 |
| CN1414008A (zh) | 2002-10-17 | 2003-04-30 | 南开大学 | 含氮甾体化合物及其制备方法 |
| US7015349B2 (en) | 2003-03-26 | 2006-03-21 | The Gillette Company | Reduction of hair growth |
| CA3062320C (en) | 2003-11-06 | 2022-11-15 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| WO2005063777A1 (en) | 2003-12-23 | 2005-07-14 | Corus Pharma | Benzylphosphate and substituted benzylphosphate prodrugs for the treatment of pulmonary inflammation |
| WO2005079523A2 (en) * | 2004-02-18 | 2005-09-01 | University Of Georgia Research Foundation, Inc. | Novel teleost derived antimicrobal polypeptides |
| AU2005216251B2 (en) | 2004-02-23 | 2011-03-10 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| US20050192257A1 (en) | 2004-02-26 | 2005-09-01 | Peyman Gholam A. | Predictors for patients at risk for glaucoma from steroid therapy |
| TW200539855A (en) | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
| NZ579482A (en) | 2004-06-01 | 2011-02-25 | Genentech Inc | Antibody drug conjugates and methods |
| EP1602931A1 (en) * | 2004-06-03 | 2005-12-07 | Universiteit Leiden | SR-A antagonists |
| US7541330B2 (en) | 2004-06-15 | 2009-06-02 | Kosan Biosciences Incorporated | Conjugates with reduced adverse systemic effects |
| DE602004017164D1 (de) | 2004-08-09 | 2008-11-27 | Deutsches Krebsforsch | Albuminkonjugate, die eine Glucuron-Verknüpfung enthalten |
| TW200616604A (en) | 2004-08-26 | 2006-06-01 | Nicholas Piramal India Ltd | Nitric oxide releasing prodrugs containing bio-cleavable linker |
| US20080305044A1 (en) | 2004-11-29 | 2008-12-11 | Seattle Genetics, Inc. | Engineered Antibodies and Immunoconjugates |
| WO2006135371A1 (en) | 2005-06-09 | 2006-12-21 | Kosan Biosciences Incorporated | Conjugates with reduced adverse systemic effects |
| US20100209508A1 (en) | 2005-06-14 | 2010-08-19 | Corus Pharma, Inc. | Substituted Phenylphosphates as Mutual Prodrugs of Steroids and ß-Agonists for the Treatment of Title Pulmonary Inflammation and Bronchoconstriction |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| CN102585002A (zh) | 2006-06-02 | 2012-07-18 | 瑞泽恩制药公司 | 人il-6受体的高亲和力抗体 |
| US8354508B2 (en) * | 2006-07-21 | 2013-01-15 | Diadexus, Inc. | PRO115 antibody compositions and methods of use |
| EP2109617A1 (en) | 2007-02-05 | 2009-10-21 | Nicox S.A. | Nitric oxide releasing steroids |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| ES2731432T3 (es) | 2007-05-23 | 2019-11-15 | Ventana Med Syst Inc | Transportadores poliméricos para inmunohistoquímica e hibridación in situ |
| CN104383553A (zh) | 2007-06-25 | 2015-03-04 | 恩多塞特公司 | 含有亲水性间隔区接头的共轭物 |
| EP2170054A4 (en) | 2007-06-28 | 2012-08-08 | Capsutech Ltd | TARGETING CONJUGATES WITH ACTIVE SUBSTANCES ENCAPLED IN CYCLODEXTRIN POLYMERS |
| CN101397328A (zh) | 2007-09-27 | 2009-04-01 | 天津药业研究院有限公司 | 一氧化氮供体型糖皮质激素 |
| DK2214646T3 (da) | 2007-10-05 | 2021-10-04 | Univ Wayne State | Dendrimers for sustained release of compounds |
| PE20091525A1 (es) | 2007-12-21 | 2009-09-25 | Schering Corp | Agonista del receptor glucocorticoide c-20-c21 sustituido |
| CN102099368A (zh) | 2007-12-21 | 2011-06-15 | 先灵公司 | 作为糖皮质激素受体激动剂的c-21硫醚 |
| CA2722109A1 (en) | 2008-04-30 | 2009-11-05 | Immunogen, Inc. | Potent conjugates and hydrophilic linkers |
| TW201010707A (en) | 2008-06-10 | 2010-03-16 | Gilead Sciences Inc | Corticosteroid linked beta-agonist compounds for use in therapy |
| JP5622117B2 (ja) | 2008-07-21 | 2014-11-12 | ポリテリクスリミテッド | 生体分子を接合するための新規な試薬及び方法 |
| AU2009273251B2 (en) | 2008-07-22 | 2014-12-18 | Ablynx Nv | Amino acid sequences directed against multitarget scavenger receptors and polypeptides |
| TWI465459B (zh) | 2009-03-09 | 2014-12-21 | Mikasa Seiyaku Co Ltd | 類固醇化合物 |
| WO2010126953A1 (en) | 2009-04-29 | 2010-11-04 | Gilead Sciences, Inc. | Corticosteroid linked beta-agonist compounds for use in therapy |
| WO2010132743A1 (en) | 2009-05-15 | 2010-11-18 | Gilead Sciences, Inc. | Corticosteroid beta-agonist compounds for use in therapy |
| CA2770626A1 (en) | 2009-08-10 | 2011-02-17 | Mark Smith | Functionalisation of solid substrates |
| WO2011020107A2 (en) | 2009-08-14 | 2011-02-17 | Georgetown University | Compositions and methods for detection and treatment of breast cancer |
| GB0917044D0 (en) | 2009-09-29 | 2009-11-18 | Cytoguide As | Agents, uses and methods |
| GB0917054D0 (en) | 2009-09-29 | 2009-11-11 | Cytoguide As | Agents, uses and methods |
| WO2011081937A1 (en) | 2009-12-15 | 2011-07-07 | Gilead Sciences, Inc. | Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy |
| WO2011090940A1 (en) | 2010-01-19 | 2011-07-28 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
| WO2011103389A1 (en) * | 2010-02-19 | 2011-08-25 | Cornell University | Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases |
| DK2528625T3 (da) | 2010-04-15 | 2013-10-14 | Spirogen Sarl | Pyrrolobenzodiazepiner og konjugater deraf |
| WO2012005982A2 (en) | 2010-07-06 | 2012-01-12 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Reporter for rna polymerase ii termination |
| WO2012011591A1 (ja) * | 2010-07-23 | 2012-01-26 | 武田薬品工業株式会社 | 縮合複素環化合物およびその用途 |
| EP2947151A1 (en) | 2010-08-02 | 2015-11-25 | Regeneron Pharmaceuticals, Inc. | Binding proteins comprising vl domains |
| UA109150C2 (xx) | 2010-09-01 | 2015-07-27 | Аміди n-(тетразол-5-іл)- або n-(триазол-5-іл)арилкарбонової кислоти та їх застосування як гербіцидів | |
| CN105399831A (zh) | 2010-10-29 | 2016-03-16 | 伊缪诺金公司 | 非拮抗性egfr结合分子及其免疫偶联物 |
| WO2012145632A1 (en) | 2011-04-21 | 2012-10-26 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
| CN110078789A (zh) | 2011-05-27 | 2019-08-02 | Ambrx 公司 | 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途 |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| BR112014009070B1 (pt) | 2011-10-14 | 2021-11-23 | Medimmune Limited | Método de síntese e intermediários úteis na preparação de pirrolobenzo-diazepinas |
| SG11201401021TA (en) | 2011-10-14 | 2014-08-28 | Spirogen Sarl | Pyrrolobenzodiazepines |
| BR112014009055B1 (pt) | 2011-10-14 | 2021-12-14 | Seattle Genetics, Inc. | Compostos pirrolobenzodiazepinas, conjugados alvos, ligante de fármaco e uso dos ditos conjugados para tratar uma doença proliferativa |
| JP6393617B2 (ja) | 2011-10-14 | 2018-09-19 | シアトル ジェネティクス，インコーポレーテッド | ピロロベンゾジアゼピンおよび標的コンジュゲート |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| IN2014CN04961A (es) | 2011-12-05 | 2015-09-18 | Igenica Biotherapeutics Inc | |
| GB201122325D0 (en) | 2011-12-23 | 2012-02-01 | Cytoguide As | Novel formulations |
| NZ631565A (en) * | 2012-03-14 | 2016-07-29 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| CN104619350A (zh) | 2012-06-14 | 2015-05-13 | Ambrx公司 | 结合到核受体配体多肽的抗psma抗体 |
| AU2013328774B2 (en) | 2012-10-11 | 2017-11-30 | Ascendis Pharma A/S | Diagnosis, prevention and treatment of diseases of the joint |
| JP2015536323A (ja) | 2012-10-16 | 2015-12-21 | エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． | 非天然アミノ酸を含む薬物送達結合体および使用方法 |
| HUE038285T2 (hu) | 2012-10-23 | 2018-10-29 | Synaffix Bv | Módosított antitest, antitest-konjugátum és eljárás ezek elõállítására |
| WO2014065575A1 (ko) | 2012-10-25 | 2014-05-01 | 주식회사유한양행 | 4,5-다이하이드로-1h-피라졸 유도체 또는 그의 염 및 이를 포함하는 약학 조성물 |
| RU2664463C2 (ru) | 2012-12-24 | 2018-08-17 | Эббви Инк. | Белки, связывающие рецептор пролактина, и их применение |
| MX2015011367A (es) | 2013-03-13 | 2015-12-16 | Seattle Genetics Inc | Ciclodextrina y formulaciones de conjugados anticuerpo-farmaco. |
| EP2988786A4 (en) | 2013-04-22 | 2016-12-21 | Avelas Biosciences Inc | COMPOSITIONS AND METHODS OF USE FOR SELECTIVE DRUG DELIVERY |
| US11229711B2 (en) | 2013-06-06 | 2022-01-25 | Magenta Therapeutics, Inc. | Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use |
| JP6744212B2 (ja) | 2013-06-21 | 2020-08-19 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | ポリペプチドの酵素的結合 |
| JPWO2015005459A1 (ja) | 2013-07-10 | 2017-03-02 | 生化学工業株式会社 | 呼吸器投与用の医薬組成物 |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| EA201690780A1 (ru) | 2013-10-15 | 2016-08-31 | Сиэтл Дженетикс, Инк. | Пегилированные лекарственные средства-линкеры для улучшенной фармакокинетики конъюгатов лиганд-лекарственное средство |
| CN103694375B (zh) | 2013-12-13 | 2016-10-05 | 北京大学 | 一种三萜-环糊精共价化合物及其制备方法和用途 |
| EP3096747B1 (en) | 2014-01-24 | 2021-08-25 | Centre National de la Recherche Scientifique | Orally available compounds, a process for preparing the same and their uses as anti-adhesive drugs for treating e. coli induced inflammatory bowel diseases such as crohn's disease |
| US10550190B2 (en) | 2014-04-04 | 2020-02-04 | Merck Sharp & Dohme Corp. | Phosphate based linkers for intracellular delivery of drug conjugates |
| PT3129063T (pt) | 2014-04-10 | 2021-04-01 | Daiichi Sankyo Europe Gmbh | Conjugado anticorpo anti-her3-fármaco |
| CA2950155C (en) | 2014-06-02 | 2021-11-23 | Regeneron Pharmaceuticals, Inc. | Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses |
| US20170189549A1 (en) | 2014-06-13 | 2017-07-06 | Glykos Finland Oy | Payload-Polymer-Protein Conjugates |
| RU2731055C2 (ru) | 2014-12-03 | 2020-08-28 | Дженентек, Инк. | Конъюгаты антитела к staphylococcus aureus с рифамицином и их применение |
| CA2966211A1 (en) | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof |
| EP3230283A1 (en) | 2014-12-09 | 2017-10-18 | AbbVie Inc. | Bcl-xl inhibitory compounds and antibody drug conjugates including the same |
| BR112017012351A2 (pt) | 2014-12-09 | 2018-02-27 | Abbvie Inc | compostos inibidores de bcl xl que têm permeabilidade celular baixa e conjugados de fármaco-anticorpo que incluem os mesmos |
| WO2016120891A1 (en) | 2015-01-30 | 2016-08-04 | Coral Drugs Pvt. Ltd. | Novel process for preparation of glucocorticoid steroids |
| JP6993958B2 (ja) * | 2015-07-06 | 2022-02-04 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 多重特異性抗原結合分子およびその使用 |
| AU2016321431C1 (en) | 2015-09-10 | 2022-01-13 | Tambo, Inc. | Bioorthogonal compositions |
| US11510993B2 (en) | 2015-10-06 | 2022-11-29 | Merck Sharp & Dohme Llc | Antibody drug conjugate for anti-inflammatory applications |
| WO2017132103A2 (en) | 2016-01-29 | 2017-08-03 | Merck Sharp & Dohme Corp. | Phosphonate linkers and their use to facilitate cellular retention of compounds |
| US11786603B2 (en) | 2016-02-26 | 2023-10-17 | Regeneron Pharmaceuticals, Inc. | Optimized transglutaminase site-specific antibody conjugation |
| SG11201807827VA (en) | 2016-03-25 | 2018-10-30 | Seattle Genetics Inc | Process for the preparation of pegylated drug-linkers and intermediates thereof |
| GB201608936D0 (en) | 2016-05-20 | 2016-07-06 | Polytherics Ltd | Novel conjugates and novel conjugating reagents |
| DK3464318T3 (da) | 2016-06-02 | 2021-06-28 | Abbvie Inc | Glucocorticoidreceptoragonist og immunkonjugater deraf |
| AU2017277916A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-CD98 antibodies and antibody drug conjugates |
| US10772972B2 (en) | 2016-09-23 | 2020-09-15 | Regeneron Pharmaceuticals, Inc. | Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof |
| AU2017359043B2 (en) | 2016-11-08 | 2022-06-16 | Regeneron Pharmaceuticals, Inc. | Steroids and protein-conjugates thereof |
| WO2018213082A1 (en) | 2017-05-18 | 2018-11-22 | Regeneron Pharmaceuticals, Inc. | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof |
| AU2018270784B2 (en) | 2017-05-18 | 2024-05-16 | Regeneron Pharmaceuticals, Inc. | Cyclodextrin protein drug conjugates |
| US11629122B2 (en) | 2017-05-24 | 2023-04-18 | The Board Of Regents Of The University Of Texas System | Linkers for antibody drug conjugates |
| CN108853514B (zh) | 2017-08-18 | 2022-07-22 | 四川百利药业有限责任公司 | 具有两种不同药物的抗体药物偶联物 |
| CN109106951A (zh) | 2017-08-18 | 2019-01-01 | 四川百利药业有限责任公司 | 一种喜树碱-抗体偶联物 |
| IL274427B1 (en) * | 2017-11-07 | 2024-07-01 | Regeneron Pharma | Hydrophilic linkers for drug-antibody conjugates |
| AU2019205542A1 (en) | 2018-01-08 | 2020-07-16 | Regeneron Pharmaceuticals, Inc. | Steroids and antibody-conjugates thereof |
| CN113905767A (zh) | 2019-01-08 | 2022-01-07 | 里珍纳龙药品有限公司 | 无痕连接体及其蛋白质偶联物 |
-
2019
- 2019-05-08 MX MX2020011546A patent/MX2020011546A/es unknown
- 2019-05-08 CN CN201980046191.6A patent/CN112533951A/zh active Pending
- 2019-05-08 JP JP2020562649A patent/JP2021523147A/ja active Pending
- 2019-05-08 BR BR112020022400-6A patent/BR112020022400A2/pt unknown
- 2019-05-08 CA CA3098453A patent/CA3098453A1/en active Pending
- 2019-05-08 AU AU2019265703A patent/AU2019265703A1/en active Pending
- 2019-05-08 EP EP19725564.9A patent/EP3790899A1/en active Pending
- 2019-05-08 US US16/407,099 patent/US11377502B2/en active Active
- 2019-05-08 SG SG11202010909RA patent/SG11202010909RA/en unknown
- 2019-05-08 KR KR1020207034456A patent/KR20210008008A/ko unknown
- 2019-05-08 WO PCT/US2019/031383 patent/WO2019217591A1/en unknown
-
2020
- 2020-11-04 PH PH12020551865A patent/PH12020551865A1/en unknown
- 2020-11-05 CL CL2020002873A patent/CL2020002873A1/es unknown
- 2020-11-30 CO CONC2020/0015084A patent/CO2020015084A2/es unknown
-
2022
- 2022-04-22 US US17/727,432 patent/US20230079407A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019217591A5 (es) | ||
| JP6449366B2 (ja) | 抗ｔｒｏｐ２抗体−薬物コンジュゲート | |
| JP2024081770A (ja) | 抗ｈｅｒ２抗体－薬物コンジュゲート | |
| KR102346223B1 (ko) | 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도 | |
| KR20220017946A (ko) | 항-b7-h4 항체-약물 접합체 및 이의 의학적 용도 | |
| RU2019138337A (ru) | Конъюгаты на основе антитела, содержащие агонист toll-подобного рецептора, и виды комбинированной терапии | |
| TW202214306A (zh) | 抗ｃｄ７９ｂ抗體藥物偶聯物、其製備方法及其醫藥用途 | |
| US20190330321A1 (en) | Antagonist antibodies that bind to human tgfb1, tgfb2 and to tgfb3 and their use for the treatment of lung fibrosis | |
| KR102366114B1 (ko) | FcRn에 특이적인 항체 | |
| TW201609133A (zh) | 配體－細胞毒性藥物偶聯物、其製備方法及其應用 | |
| WO2021067820A1 (en) | Formulation of antibody-drug conjugate | |
| CA3162754A1 (en) | Anti-claudin antibody-drug conjugate and pharmaceutical use thereof | |
| JP7054573B2 (ja) | Ｐｄ－１結合抗体及びその用途 | |
| JP2024501121A (ja) | 癌の処置 | |
| TW202144012A (zh) | 抗體－藥物偶聯物及其醫藥用途 | |
| CN113121639B (zh) | 澳瑞他汀类似物及其偶联物、其制备方法及其应用 | |
| IL272268B (en) | flow meter and repeater | |
| TW202342025A (zh) | Gpc3抗體藥物偶聯物及其用途 | |
| CN117460540A (zh) | 艾日布林衍生物的药物偶联物 | |
| WO2021121204A1 (zh) | 抗cea抗体-依喜替康类似物偶联物及其医药用途 | |
| WO2023104188A1 (en) | Anti-cdh6 antibodies and antibody-drug conjugates thereof | |
| WO2023046003A1 (zh) | 抗体药物偶联物及其制备方法和医药用途 | |
| CN117751139A (zh) | 抗Nectin-4抗体依喜替康缀合物 | |
| TW202408589A (zh) | 抗ror1抗體及抗體結合物、包含抗ror1抗體或抗體結合物之組合物，及製造及使用抗ror1抗體及抗體結合物之方法 | |
| CN118403182A (zh) | 抗密蛋白抗体药物偶联物及其医药用途 |